← Back to Screener
Kyverna Therapeutics, Inc. Common Stock (KYTX)
Price$9.53
Favorite Metrics
Price vs S&P 500 (26W)26.93%
Price vs S&P 500 (4W)4.25%
Market Capitalization$568.13M
All Metrics
Book Value / Share (Quarterly)$3.85
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.56
Price vs S&P 500 (YTD)-2.64%
EPS (TTM)$-3.65
10-Day Avg Trading Volume0.68M
EPS Excl Extra (TTM)$-3.65
EPS (Annual)$-3.34
ROI (Annual)-47.48%
Cash / Share (Quarterly)$4.62
ROA (Last FY)-41.69%
EBITD / Share (TTM)$-3.80
Cash Flow / Share (Annual)$-2.56
P/B Ratio2.45x
P/B Ratio (Quarterly)2.31x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-13174.00x
ROA (TTM)-66.65%
EPS Incl Extra (Annual)$-3.34
Current Ratio (Annual)7.75x
Quick Ratio (Quarterly)7.65x
3-Month Avg Trading Volume1.22M
52-Week Price Return321.52%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)80.87x
Asset Turnover (Annual)0.10x
52-Week High$13.67
EPS Excl Extra (Annual)$-3.34
26-Week Price Return30.92%
Quick Ratio (Annual)7.65x
13-Week Price Return14.22%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)7.75x
Enterprise Value$469.092
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-411.29%
Cash / Share (Annual)$4.62
3-Month Return Std Dev80.30%
Net Income / Employee (TTM)$-1
ROE (Last FY)-47.64%
EPS Basic Excl Extra (Annual)$-3.34
Total Debt / Equity (Quarterly)0.11x
EPS Incl Extra (TTM)$-3.65
ROI (TTM)-78.81%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)291.69%
Year-to-Date Return0.00%
5-Day Price Return-1.88%
EPS Normalized (Annual)$-3.34
Net Profit Margin (Annual)-411.29%
Month-to-Date Return8.92%
EBITD / Share (Annual)$-3.29
Operating Margin (Annual)-418.28%
LT Debt / Equity (Annual)0.11x
LT Debt / Equity (Quarterly)0.11x
EPS Basic Excl Extra (TTM)$-3.65
P/B Ratio (Annual)2.31x
Book Value / Share (Annual)$3.85
Price vs S&P 500 (13W)13.53%
Beta1.89x
Revenue / Share (TTM)$0.00
ROE (TTM)-81.41%
52-Week Low$1.78
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KYTXKyverna Therapeutics, Inc. Common Stock | — | — | — | — | $9.53 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on cell therapies for autoimmune diseases. Its pipeline includes KYV-101, an autologous CD19 CAR T-cell therapy, and KYV-201, an allogeneic version designed for multiple autoimmune indications.